Bio-Rad (BIO) President & COO Granted 6,850 RSUs on 09/05/2025

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired 6,850 restricted stock units (RSUs) on 09/05/2025, each representing a contingent right to one share of Bio-Rad Class A common stock.

Rhea-AI Filing Summary

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired 6,850 restricted stock units (RSUs) on 09/05/2025, each representing a contingent right to one share of Bio-Rad Class A common stock. The RSUs were granted with a $0 per-unit price and vest over four years at 25% per year on each annual anniversary of the grant. Following the transaction, DiVincenzo beneficially owns 6,850 shares subject to these RSUs, held directly. The Form 4 was signed on 09/08/2025. No other derivatives or dispositions are reported in this filing.

Positive

• Executive ownership increased through a 6,850 RSU grant, aligning management incentives with shareholders
• Time-based vesting over four years promotes retention and long-term performance focus

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine executive equity grant increases management alignment without immediate dilution or cash outlay.

The 6,850 RSU award to the President & COO is a common compensation vehicle that vests over four years, linking pay to retention and future stock performance. The $0 grant price indicates standard restricted units rather than an option; they convert to one share each on vesting, which can modestly increase share count when settled. This transaction is informational and not likely to materially affect near-term financial metrics or valuation.

Corporate Governance Expert

TL;DR: Standard executive grant that supports retention and aligns executive incentives with shareholders.

The grant follows typical governance practice: time-based vesting over four years at annual 25% tranches. Reporting as a Form 4 is routine for insiders. Key governance considerations—such as whether the grant was approved by the compensation committee or part of a broader equity plan—are not included in this filing and would appear in proxy disclosures or grant notices.

Insider Trade Summary

Grant/Award: 6,850 shares

Grant/Award 1 txn

Insider DiVincenzo Jonathan P.

Role President & COO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	6,850	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 6,850 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
2. F2. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BIO insider Jonathan P. DiVincenzo acquire on 09/05/2025?

He was granted 6,850 restricted stock units (RSUs), each representing a contingent right to one share of Bio-Rad Class A common stock.

What is the vesting schedule for the RSUs in the BIO Form 4?

The RSUs vest over four years at 25% per year on each annual anniversary of the grant.

How much did Jonathan P. DiVincenzo pay for the RSUs reported on the Form 4?

The RSUs were granted at a $0 per-unit price as reported in the filing.

How many RSU-derived shares does DiVincenzo beneficially own following the transaction?

Following the reported transaction he beneficially owns 6,850 shares (subject to the RSU vesting).

When was the Form 4 signed and filed for this transaction?

The signature on the Form 4 is dated 09/08/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DiVincenzo Jonathan P.

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & COO

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	09/05/2025		A		6,850		(2)	(2)	Bio-Rad A Common Stock	6,850	$0	6,850	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

2. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Jonathan P. DiVincenzo	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.